Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin + weekly paclitaxel plus bevacizumab as first-line treatment in epithelial ovarian cancer
2008-008336-85Phase 2Completed
- Sponsor
- Roche
- Start
- Mar 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC) and 1 more, sponsored by Roche. Primary endpoint: Progression-free survival. Started Mar 2009; status: completed.
02
Drugs
bevacizumab
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)ovarian cancer
Beyond the preview
Go deeper on 2008-008336-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008336-85.